- Revolutionizing T Cell Immunotherapies
Revolutionizing T Cell Immunotherapies
Published on 9 September 2021
CAR T Cell Therapy Shows Promise for Treating Several Applications
Pharma Tech Outlook interviewed our CEO Scott Deeter, who shares how InVitria is revolutionizing T cell immunotherapies.
InVitria offers the experience and expertise to help you supplement your media of choice with its full line of animal-free, serum-free, recombinant individual cell-culture components. If you would like to read further about InVitria’s animal-, human-, and blood-free T Cell Media, check out our immunotherapy applications page to see how our proven performance and consistency could transform your application.
Connect with our product applications team today to see how you can maximize your application with Serum-Free T-Cell Media.Immunotherapy
Download PDF Here